Viral hemorrhagic fevers (VHFs) refer to a group of illnesses that are caused by several distinct families of viruses. In general, the term "viral hemorrhagic fever" is used to describe a severe multisystem syndrome (multisystem in that multiple organ systems in the body are affected). Characteristically, the overall vascular system is damaged, and the body's ability to regulate itself is impaired. These symptoms are often accompanied by hemorrhage (bleeding); however, the bleeding is itself rarely life-threatening. While some types of hemorrhagic fever viruses can cause relatively mild illnesses, many of these viruses cause severe, life-threatening disease.
Individuals who are infected by Zika virus after having dengue fever do not appear to become more severely ill than people with Zika who have never had dengue.
If there is anything scientists are certain of when it comes to bats and their supposed role in causing human disease, it is that they still have a lot to learn.
There are a large number of infections that are borne and carried by animals and spread to humans. These are called zoonotic diseases wherein the microbe or pathogen jumps from one species of the animals to another. Now a new study has ranked mammals based on the risk they pose to humans in terms of spreading infectious diseases to humans.
Before Ebola virus ever struck West Africa, locals were already on the lookout for a deadly pathogen: Lassa virus.
Why mosquito-borne dengue virus causes more severe disease in some individuals, including hemorrhagic fever with or without shock, remains controversial and researchers are focusing on the factors related to the interaction between the virus and the host immune system, including the role of mast cells.
Before Ebola virus ever struck West Africa, locals were already on the lookout for a deadly pathogen: Lassa virus. With thousands dying from Lassa every year-;and the potential for the virus to cause even larger outbreaks- researchers are committed to designing a vaccine to stop it.
A team of international scientists led by Dr. Michael Jarvis at the University of Plymouth has received funding in excess of £408,000 from Innovate UK to develop a new and economic vaccine designed to halt the spread of highly pathogenic 'zoonotic' (spreading from animals to humans) infectious diseases.
The Global Health Innovative Technology Fund, a unique Japanese public-private partnership formed to battle infectious diseases around the globe, today announced 11 new investments totaling US$23 million that could help deliver a range of new innovative therapies for a host of debilitating conditions.
Transmission of the mosquito-borne dengue virus appears to be largely driven by infections centered in and around the home, with the majority of cases related to one another occurring in people who live less than 200 meters apart, new research led by the Johns Hopkins Bloomberg School of Public Health and the University of Florida suggests.
The majority of dengue virus infections appear to happen very close to home and are transmitted from the same family of mosquitoes, suggests new research led by the University of Florida and the Johns Hopkins Bloomberg School of Public Health.
Although Zika and dengue are considered different virus "species," they are so closely related that the immune system treats Zika just like another version of dengue, report researchers at La Jolla Institute for Allergy and Immunology.
For most people who contract it, dengue fever is a relatively mild-mannered disease--at least the first time around. For some, however, a subsequent infection by the virus unleashes a vicious and potentially deadly illness.
The Georgia State University Research Foundation has entered into a research collaboration agreement with GeoVax Labs, Inc., a Georgia-based biotechnology company developing human vaccines, to advance development of a therapeutic vaccine for treatment of chronic Hepatitis B infections.
The only approved vaccine for dengue may actually increase the incidence of dengue infections requiring hospitalization rather than preventing the disease if health officials aren't careful about where they vaccinate, new public health research published Sept. 2 in Science suggests.
Scientists at The Scripps Research Institute now have a high-resolution view of exactly how the experimental therapy ZMapp targets Ebola virus.
A newly identified requirement of a modified human protein in ebolavirus (EBOV) replication, may unlock the door for new approaches to treating Ebola.
A biopharmaceutical company collaborating with Hawai'i scientists on an Ebola vaccine announced encouraging news about its vaccine today.
Viruses can't live without us -- literally. As obligate parasites, viruses need a host cell to survive and grow. Scientists are exploiting this characteristic by developing therapeutics that close off pathways necessary for viral infection, essentially stopping pathogens in their tracks.
Ebola virus samples taken from patients in Liberia in June 2015 are strikingly similar in their genetic makeup to other Ebola virus sequences from Western Africa, according to research published online today in the journal Science Advances. The study sheds light on several aspects of the "flare-ups" that have occurred in Liberia since the country was initially declared free of Ebola virus disease.
As of January 31, 2016, a total of 28,639 cases and 11,316 deaths have been attributed to Ebola, figures that are assumed to significantly underestimate the actual scope of the 2014 Ebola Hemorrhagic Fever outbreak in West Africa. In the United States, there were also two imported cases and two locally acquired cases reported in September/October 2014.